X-Chem has been leading the DEL field for more than a decade. During those years we have attained an unparalleled track record of success. Each of our 85+ licenses represent an instance where our partners decided to commit to the chemical matter discovered from our platform. Most of these successes remain proprietary to our partners, but a handful of examples have been recently published in peer-reviewed journals. We have compiled these examples into the list below. These examples span a wide variety of therapy areas and target classes. Some represent our older and more peptidic libraries and others exemplify more contemporary and lead-like library designs. Click below to take a tour through X-Chem’s track record of success.

Published Successes from X-Chem and our Partners

Enzymes
Target: HAO1 Inhibitor, IC50= 25 nM
Therapy Area: Rare Disease
Receptors
Target: ERa Binder, IC50= 50 nM
Therapy Area: Oncology
Receptors
Target: PAR2 Antagonist, IC50= 23 nM
Therapy Area: Neurology
Receptors
Target: PAR2 Antagonist, EC50= 230 nM
Therapy Area: Neurology
Enzymes
Target: ATX Inhibitor, IC50= 55 nM
Therapy Area: Inflammation
Kinases
Target: TAK1 Inhibitor, IC50= 5 nM
Therapy Area: Oncology
Enzymes
Target: sEH Inhibitor, IC50= 2 nM
Therapy Area: Inflammation
Kinases
Target: BTK Inhibitor, IC50= 2 nM
Therapy Area: Oncology
Kinases
Target: BTK Inhibitor, IC50= 60 nM (1h)
Therapy Area: Oncology
Kinases
Target: MerTK Inhibitor, IC50= 5 nM
Therapy Area: Oncology
Enzymes
Target: KMO Inhibitor, IC50= 14 nM
Therapy Area: Oncology
Protein Protein Interaction
Target: ATAD2 Inhibitor, IC50= 25 nM
Therapy Area: Oncology
Protein Protein Interaction
Target: Mcl-1 Inhibitor, IC50= <3 nM
Therapy Area: Oncology
Enzymes
Target: InhA Inhibitor, IC50 = 26 nM
Therapy Area: Tuberculosis